Bendamustin in association with Rituximab (BR) in the treatment of patients with relapsed/refractory lymphoid neoplasm. A GISL retrospective study

Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

Increase of CCR7- CD45RA+ CD8 T cells (TEMRA) in Chronic Graft-versus-host Disease

Among the late effects of hematopoietic stem cell transplantation (HSCT), chronic graft-vs-host disease (cGVHD) still remains as the major determinant of long-term outcome and quality of life. The disease typically appears between 3 months to 1.5 years following an allogeneic transplantation and is characterized by symptoms similar to those of autoimmune disease.

Chronic myeloid leukemia as second malignancy; restrospective multicentric study